Density: 1.4804 (estimated), alternatively given as 2.12g/cm³
Solubility: Soluble in dimethyl sulfoxide (DMSO) >10mg/mL
pKa: 12.56±0.70 (predicted)
λmax: 263nm (EtOH)
Chemical and Biological Properties
Chemical Class: Nucleotide analogue, second-generation purine nucleoside analogue
Mechanism of Action: Combines the advantages of fludarabine and cladribine, inhibiting both DNA polymerase and ribonucleotide reductase.
Biological Activity: Exhibits anticancer activity and induces apoptosis. In various leukemic and solid tumor cell lines, Clofarabine demonstrates strong growth inhibitory and cytotoxic effects in vitro.
Pharmaceutical Characteristics
Indications: Currently the only drug suitable for the treatment of pediatric leukemia and specifically for pediatric acute lymphocytic leukemia (ALL).
Dosage and Administration: Can be administered intravenously or orally. Specific dosage and administration should be determined based on patient condition and medical guidance.
Adverse Reactions: May include hematological reactions such as leukopenia, neutropenia, thrombocytopenia, and anemia; digestive system reactions such as anorexia, nausea, and vomiting; neurological reactions such as fatigue, drowsiness, and headache; cardiovascular reactions such as tachycardia and hypertension; as well as potential liver toxicity, respiratory distress, hematuria, and other adverse reactions.
